Since EGFR per se acts as a major cargo of EVs and contributes to tumor metastasis, angiogenesis, and TKI resistance [3], exosomal delivery of JMJD5 may represent a putative strategy for EGFR-targeted therapy of NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.